GLIPIZ

Other Theraputic Areas Alpha Blocker Analgesic Anesthetic Anthelmintic Anti-Acne Anti-Asthmatic Anti-Bacterial Anti-Biotic Anti-Coagulant Anti-Depressant Anti-Diabetic Anti-Dyslipidemic Anti-Emetic Anti-Epileptic Anti-Fungal Anti-Histamine Anti-Hypertensive Anti-Inflammatory Anti-Lipemic Anti-Melasma Anti-Migraine Anti-Muscarinic Anti-Osteoporotic Anti-Platelet Anti-Psychotic Anti-Septic Anti-Spasmodic ARNi Benzodiazepine Beta-Blocker Cardiology Corticosteroids Cough Suppressant Decongestant Dermatology Diabetology Emollient Expectorant Funny Channel Blocker Gabapentenoid General Care Hematinic Immunomodulatory Loop Diuretic Lubricant Neuropsychiatry NSAIDs Proton Pump Inhibitor SSRI Supplement Sympathomimetic Vasoprotective Vitamin

GLIPIZ

Generic Name

Glipizide

Composition

Glipizide BP 5 mg

Dosage Type

Tablet

Pack Size

10x10

Strength

MRP

Rs. 2.5

GLIPIZ is indicated as an adjunct to diet and exercise for the control of hyperglycemia and its associated symptomatology in patients with non-insulin-dependent diabetes mellitus.

Recommended dose is 5mg given before breakfast.
Maximum recommended once daily dose is 15mg and the maximum recommended total dose is 40mg.
Some patients may be effectively controlled on a once-a-day regimen, while others show better response with divided dosing. Total daily doses above 15 mg should ordinarily be divided. Total daily doses above 30 mg have been safely given on a bid basis to long-term patients. In elderly patients, debilitated or malnourished patients, and patients with impaired renal or hepatic function, the initial and maintenance dosing should be conservative to avoid hypoglycemic reactions.

Patients receiving insulin agents: As with other sulphonylurea class hypoglycemic, many stable non-insulin-dependent diabetic patients receiving insulin may be safely placed on GLIPIZ.

Patients receiving other oral hypoglycaemic agents: As with other sulphonylurea class hypoglycemics, no transition period is necessary when transferring patients to GLIPIZ. Patients should be observed carefully (1-2 weeks) for hypoglycemia when being transferred from longer half-life sulphonylureas (e.g. chlorpropamide) to GLIPIZ due to potential overlapping of drug effect.

GLIPIZ is contraindicated in patients with,

Hypersensitivity to glipizide, sulfonylurea derivatives or sulfonamides.
Diabetic ketoacidosis, with or without coma
Severe renal or hepatic insufficiency
Severe thyroid dysfunction
Pregnancy

Macrovascular Outcomes
Renal and Hepatic Disease
Hypoglycemia
Loss of Control of Blood Glucose

Hypoglycemia
Gastrointestinal disturbances
Dermatologic reactions
Hematologic reactions
Metabolic reactions
Endocrine reactions

Store the medicine in a closed container at room temperature, away from heat, moisture, and direct light.

GLIPIZ 5 mg: 10×10’s

Anti-Diabetic

GLIPIZ

GLIPIZ

Related Products